orforglipron

Compound Specifications

Compound Name	Orforglipron
Development Code	LY3502970
Compound Class	Non-peptide GLP-1 Receptor Agonist (Small Molecule)
CAS Number	2381246-44-0
Developer	Eli Lilly and Company
Administration	Oral, once daily
Development Status	Phase III (obesity & type 2 diabetes)
Purity	≥98% (HPLC & LC-MS verified)
Supply Form	Raw powder; encapsulated on request
Storage	Cool, dry place. No cold chain required. Protect from light and moisture.

Available Formats & MOQs

Raw Powder
Pilot and scale quantities available. Contact us for MOQ and pricing based on your research volume. Supplied in research-grade bulk packaging with tamper-evident seals. COA included.

Encapsulated
Available on request for eligible B2B partners. Contact us to discuss dose and quantity requirements.

White Label / Formulation Support
Available for qualified B2B partners in R&D contexts. Contact us to discuss your specific requirements.

Research Context

Orforglipron acts as a selective agonist at the glucagon-like peptide-1 (GLP-1) receptor, the same receptor targeted by approved injectable agents semaglutide and tirzepatide. As a small molecule rather than a peptide, it bypasses the structural limitations that have historically confined GLP-1 agonists to injectable formats — making it the subject of significant pharmaceutical and academic interest.

Phase III clinical programmes have been investigating Orforglipron for weight management in adults with obesity and for glycaemic control in type 2 diabetes. Publicly reported data from earlier trials indicates double-digit mean weight reduction at higher doses in non-diabetic cohorts, alongside meaningful HbA1c reductions in diabetic populations. Tolerability profiles are consistent with the GLP-1 class — predominantly gastrointestinal adverse events including nausea, diarrhoea, and constipation.

Its oral format removes cold-chain requirements, simplifying logistics for multi-site research programmes and reducing operational overhead compared to injectable alternatives.

All data cited refers to publicly available clinical trial readouts. All products are supplied for research purposes only and are not intended for human or veterinary use. No claims of safety or efficacy are made.

GLP-1 Pathway Agents — Research Comparison

Compound	Format	Mechanism	Dev. Status	Cold Chain
Orforglipron	Oral (daily)	GLP-1 agonist (small molecule)	Phase III	Not required
Retatrutide	Injectable (weekly)	GLP-1 + GIP + Glucagon (triple)	Phase II/III	Required
Semaglutide	Injectable (weekly)	GLP-1 agonist (peptide)	Approved	Required
Tirzepatide	Injectable (weekly)	GLP-1 + GIP dual agonist (peptide)	Approved	Required

ⓘ For research reference only. Efficacy data is not directly comparable across studies or compounds.

Quality & Documentation

• GMP-certified manufacturing
• ISO quality management system
• HACCP-compliant production controls
• Independent third-party testing — HPLC, LC-MS, ICP-MS
• Certificate of Analysis (COA) issued per batch
• MSDS available on request
• Batch and lot traceability records
• Research Use Only labelling and export documentation included

See our Lab Testing & QA page for full methodology detail.

Who Orders Wholesale Orforglipron

• Contract Research Organisations (CROs) — metabolic disease and obesity research programmes
• University research groups — GLP-1 receptor pharmacology studies
• Pharmaceutical R&D teams — comparator compound supply for GLP-1 class research
• Qualified B2B distributors — specialist research compound distribution

See our Industries We Serve page for full B2B client detail.

Related Compounds

Buyers sourcing Orforglipron frequently also enquire about:

• Retatrutide — triple GLP-1/GIP/Glucagon agonist, injectable, Phase II/III
• MK-677 (Ibutamoren) — oral growth hormone secretagogue, metabolic research applications
• Klotho — longevity and metabolic research compound

For peptide-based weight management compounds including semaglutide analogues and related GLP-1 pathway peptides, visit our sister site Peptide-Direct.

Frequently Asked Questions

What is Orforglipron (LY3502970)?
Orforglipron is a non-peptide, orally active GLP-1 receptor agonist developed by Eli Lilly. It is a small molecule designed for once-daily oral administration, currently in Phase III development for obesity and type 2 diabetes. Available for research use only.

What is the CAS number for Orforglipron?
The CAS number for Orforglipron is 2381246-44-0.

Is Orforglipron available for consumer use?
No. It is an investigational compound for research use only. Not approved for human consumption, medical treatment, or clinical use. Supply is restricted to qualified institutional and professional B2B buyers.

How does Orforglipron differ from semaglutide or tirzepatide?
Orforglipron is a small-molecule oral GLP-1 agonist. Semaglutide and tirzepatide are injectable peptides requiring weekly administration and cold-chain storage. Orforglipron's oral format removes cold-chain requirements and simplifies logistics for research operations.

Do you provide COAs for wholesale Orforglipron?
Yes. Batch COAs and full QC documentation are available on request for all qualified buyers.

Can you supply Orforglipron for white label or formulation work?
Yes, for eligible B2B partners in R&D contexts. Contact us to discuss your specific requirements.

Legal & Safety Notice

Orforglipron is an investigational research compound. It is not approved by any regulatory authority for human consumption, medical treatment, or clinical application. All purchases are restricted to qualified institutional or professional B2B buyers. Buyers are responsible for ensuring compliance with applicable regulations in their jurisdiction.